Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy by Giaccone, G. et al.
J Cancer Res Clin Oncol (2009) 135:467–476
DOI 10.1007/s00432-008-0466-3
ORIGINAL PAPER
Epidermal growth factor receptor expression analysis 
in chemotherapy-naive patients with advanced non-small-cell 
lung cancer treated with geWtinib or placebo in combination 
with platinum-based chemotherapy
Giuseppe Giaccone · Renee B. Iacona · 
Abderrahim Fandi · Mette Janas · Judith S. Ochs · 
Roy S. Herbst · David H. Johnson 
Received: 23 June 2008 / Accepted: 12 August 2008 / Published online: 12 September 2008
©  The Author(s) 2008. This article is published with open access at Springerlink.com
Abstract
Purpose Two large, randomized, placebo-controlled trials
(IRESSA NSCLC Trial Assessing Combination Therapy;
INTACT 1 and 2) in non-small-cell lung cancer (NSCLC)
failed to show survival beneWt for geWtinib (IRESSA) in
combination with Wrst-line platinum-based chemotherapy.
Epidermal growth factor receptor (EGFR) staining was
assessed retrospectively in relation to survival response to
geWtinib in combination with chemotherapy.
Methods Tumor biopsies obtained prior to start of therapy
were assessed by immunohistochemistry for EGFR using
the Dako EGFR pharmDx assay™ (Dako, Denmark). Anal-
yses were stratiWed by trial and performed independently for
patients randomized to placebo and geWtinib as well as for
both treatment groups combined. A restricted backwards
elimination Cox regression analysis was conducted to iden-
tify independent EGFR factors that were statistically signiW-
cant (P < 0.10), and these were also tested for treatment
interaction to assess if they served as predictive factors.
Results Analyses found two statistically signiWcant EGFR-
based prognostic factors representing growth pattern and per-
cent membrane staining in patients treated with geWtinib
(P = 0.0023), placebo (P = 0.0128), and both combined
(P < 0.0001). The prognostic eVect was independent of other
known prognostic factors. There was no predictive eVect of
either the growth pattern or membrane staining variable.
Conclusions While some previous studies indicate that
higher EGFR expression correlates with poor survival, our
analyses provide statistically signiWcant evidence that the
combination of EGFR expression and growth pattern is a
strong prognostic indicator for improved survival within
this setting. The eVects of membrane staining and growth
pattern are still signiWcant when adjusting for mutation.
Keywords EGFR · NSCLC · GeWtinib · Chemotherapy · 
Tumor biopsies · Immunohistochemistry · Biomarkers
Introduction
The identiWcation of factors that may predict survival
(i.e., prognostic factors) or response to treatment (i.e.,
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(NSCLC) is an important goal, as it may, in the future,
enable identiWcation of patients with better prognosis, or
targeting of treatment to those patients most likely to
respond. One such factor worthy of consideration is the
epidermal growth factor receptor (EGFR), a member of
the erbB family of receptors. EGFR, which is expressed
or highly expressed in a variety of solid tumors, has been
implicated in the pathogenesis of human malignancies
and hence is a rational target for anticancer therapies
(Salomon et al. 1995; Woodburn 1999). Expression of
EGFR may be demonstrated by means of diVerent tech-
niques; for example, immunoblotting and immunohisto-
chemistry (IHC). Even within one technique, diVerences
in primary antibody, epitope retrieval method, visualiza-
tion system, method of interpretation, and cut-oV level
may all aVect the level of EGFR expression recorded.
This may partly explain the conXicting results on EGFR
as a prognostic indicator (Kallio et al. 2003; Merse-
burger et al. 2005; Nicholson et al. 2001).
However, in NSCLC, EGFR expression has a “weak”
association with overall survival (OS). Many studies in
NSCLC have reported an association of EGFR to poor sur-
vival (Ohsaki et al. 2000; Veale et al. 1993; Volm et al.
1998), while others report a prognostic correlation for
EGFR only in combination with other proteins like HER2-
neu (Brabender et al. 2001). However, in a review of the lit-
erature, more studies actually failed to show a signiWcant
correlation between EGFR expression and OS (Meert et al.
2002).
In order to determine whether there is any correlation
between the level of EGFR expression and OS, explor-
atory analysis of EGFR expression was performed using
diagnostic samples from patients with advanced NSCLC
participating in the Phase III INTACT (IRESSA NSCLC
Trial Assessing Combination Treatment) trials, which
failed to show survival beneWt with geWtinib (IRESSA)
(Giaccone et al. 2004; Herbst et al. 2004). In these stud-
ies, no selection based on EGFR expression was per-
formed because this was not correlated with response to
EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in pre-
clinical models (AstraZeneca data on Wle). However, it
might be theoretically possible to Wnd a subgroup of
patients with a speciWc EGFR pattern, who were pre-
dicted to beneWt signiWcantly from treatment. The
exploratory objective was to retrospectively identify
prognostic indicators for Wrst-line chemotherapy-treated
patients. We aimed to determine the prognostic eVect of
EGFR in these patients and whether prognostic eVects of
EGFR were independent of other known clinical prog-
nostic factors.
Materials and methods
Randomization
All patients were randomized to standard chemotherapy
plus one of the following: geWtinib 250 mg/day, geWtinib
500 mg/day, or placebo. Allocation to the three treatment
groups was performed by dynamic randomization (Pocock
and Simon 1975) to obtain treatment balance for the fol-
lowing stratiWcation factors: weight loss in the previous
6 months ·5% versus >5%; disease stage III versus IV;
performance status (PS) of 0 or 1 versus 2; or measurable
disease versus non-measurable disease.
Patients
Eligibility criteria have already been reported (Giaccone
et al. 2004; Herbst et al. 2004). The INTACT study was
performed in accordance with the Declaration of Helsinki,
and patients gave an informed consent prior to inclusion in
the study (Giaccone et al. 2004; Herbst et al. 2004). Dona-
tion of tumor samples was not obligatory for participation
in the INTACT studies.
Handling and assessment of tissue samples
NSCLC tissue samples were obtained prior to start of ther-
apy. The samples were formalin-Wxed and paraYn-embed-
ded according to prespeciWed guidelines. All handling of
trial material was performed in compliance with Good
Clinical and Good Laboratory Practices’ guidelines (Inter-
national Conference on Harmonisation 2001; Organisation
for Economic Co-operation and Development 2007). A
medical pathologist, blinded to treatment and outcome,
assessed sample evaluability, growth pattern, staining pat-
terns, and staining intensities. Due to the inability to evalu-
ate growth pattern, cytology specimens were excluded from
the analysis.
EGFR immunohistochemistry
Tissue specimens were stained by IHC using the validated
EGFR pharmDx™ (Dako, Denmark) assay, which utilizes
a standard staining protocol (Dako, EGFR pharmDx™
product insert) (Spaulding and Spaulding 2002). The EGFR
pharmDx™ assay detects native EGFR as well as mutant
EGFR vIII (Andersen et al. 2004). Further, the EGFR phar-
mDx™ assay has been shown not to cross-react with the
other three members of the erbB receptor family, erbB2,
erbB3, and erbB4 (Andersen et al. 2004; Spaulding and
Spaulding 2002).123
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The pattern of membrane and cytoplasmic staining was
assessed in each tumor sample. The sum of the percentages
of tumor cells was recorded with four levels of staining
intensity (no staining [0], weak [1+], moderate [2+], or
strong staining [3+]) totaling 100% (Fig. 1a–f). This was
true for both membrane and cytoplasmic staining.
The medical pathologist (MJ) categorized the growth
pattern in three categories: (1) solid, (2) glandular, or (3)
mixed solid and glandular. (1) For tumors with solid
growth pattern, as seen in squamous cell carcinoma, or
poorly diVerentiated adenocarcinoma (AC), complete stain-
ing of the membrane resulted in a staining pattern, Wgura-
tively described as chicken-wire or Wshnet staining
(Fig. 1a–c). (2) The glandular growth pattern reXects the
growth pattern of a well-diVerentiated AC, including, but
not restricted to, the growth of bronchioloalveolar carci-
noma (BAC). The maximal membrane staining in well-
diVerentiated AC is found in the basal and lateral mem-
branes, mirroring the fact that tumor cells of AC with glan-
dular growth are polarized (Fig. 1d–f). (3) Tumors with
mixed growth pattern (adenosquamous carcinoma) may
contain areas with both chicken-wire basolateral-membrane
staining. The rationale for capturing complete and basolat-
eral-membrane staining stems from the established scoring
system for HercepTestTM (Dako, Denmark), where com-
plete membrane staining in >10% of tumor cells determines
eligibility for trastuzumab treatment (Slamon et al. 1989).
Statistical analysis
Both the predictive and the prognostic eVects of EGFR
were investigated.
An exploratory analysis on OS was performed indepen-
dently for patients randomized to placebo and to geWtinib
(250 or 500 mg/day), as well as for combined treatment
groups. Analyses were stratiWed by trial. A restricted
Fig. 1 Photomicrographs of 
squamous cell carcinoma (SC) 
(a–c) and well diVerentiated 
adenocarcinoma (AC) (d–f) 
immunostained with the Dako 
(EGFR) pharmDx™ assay. In 
SC the growth pattern is solid. 
When the entire circumference 
of the cell membrane is stained 
positive, the impression of the 
tumor is that of chicken-wire or 
Wshnet. In AC the growth pattern 
is glandular, allowing for a baso-
lateral staining when the entirety 
of the membrane is stained. The 
cell membrane may have diVer-
ent staining intensities: a and d 
weak 1+ staining; b and e mod-
erate 2+ staining; c and f strong 
3+ staining123
470 J Cancer Res Clin Oncol (2009) 135:467–476backwards elimination Cox proportional hazard regression
analysis, by which only biologically relevant eliminations
took place in each step, was conducted. In each step, the
statistical model contains a term for up to three variables
(intensity level 1+, 2+, and 3+) within each of three catego-
ries: (a) membrane, (b) complete or basolateral, and (c)
cytoplasmic staining. Tests are restricted to coeYcients of
all pairs of adjacent variables within the same category
being equal. For example, the test of the coeYcient to the
variable at the lowest level (1+) being equal to zero is con-
sidered as a test for collapsing this level with the no stain-
ing level. Additionally, let us assume that in a previous step
the hypothesis that the eVect of staining being at level +1
and +2 is accepted as being equal, leading to the adjoining
of these two levels, then testing that the coeYcient to the
adjoined level is equal to zero is identical to testing whether
the adjoined level (1+ and 2+) could be further combined
with the no staining level, and thereby removed from the
model. In each step the test producing the largest P value
determines the candidate to be adjoined next.
The analyses were conducted to identify categorical and
continuous EGFR factors (growth pattern, membrane, and
cytoplasmic staining intensity and completeness of mem-
brane staining) prognostic for survival within the group of
placebo and geWtinib-treated patients, separately as well as
combined. Variables found to have a statistically signiWcant
prognostic eVect within at least one of the two treatment
groups were also tested for treatment interaction, to deter-
mine if they served as predictive factors.
It was further analyzed whether EGFR-related variables,
found to be statistically signiWcant prognostic factors, had
an eVect of their own, independent of other potential prog-
nostic factors such as gender, PS, stage, histology, and site
of metastasis. This was done by repeating the above-men-
tioned procedure based on the EGFR-related variables in
combination with the potential clinical prognostic factors.
Tests were performed at the 10% two-sided signiWcance
level (i.e., P < 0.10 was considered statistically signiWcant).
Results
Demographics
A total of 631 patients had tumor samples available and
provided consent to this exploratory part of the INTACT
studies. Tissue samples that were fully evaluable for EGFR
were available for 516 patients (219 and 297 from INTACT
1 and 2, respectively).
Comparison of the demographic factors and patient dis-
ease characteristics such as histology, PS, stage, and site of
metastasis revealed that this patient population, with a
tumor sample fully evaluable for EGFR, was similar to that
of both INTACT trials from whom tumor samples were less
than fully evaluable for EGFR or not evaluable, and repre-
sentative of the full INTACT population (data on Wle).
Prognostic and predictive eVect
Prognostic eVect
The two EGFR-related variables of growth pattern and
membrane staining were found to have statistically signiW-
cant prognostic eVects, both in patients treated with geWti-
nib (P = 0.0023) and placebo (P = 0.0128), as well as in the
two groups combined (P < 0.0001) (Table 1).
There was no statistically signiWcant diVerence in OS
between patients having tumors with a glandular growth
pattern and those having tumors with a mixed growth pat-
tern in either of the treatment groups (data not shown).
Therefore, these patients (glandular/mixed) were combined
and will subsequently be referred to as “glandular patients”.
The others will be referred to as “solid patients”. Glandular
patients had statistically signiWcantly better survival than
solid patients when the two treatment groups were com-
bined (P = 0.0001) or considered separately (placebo,
P = 0.0220; geWtinib, P = 0.0014) (Table 1). This prognos-
tic eVect was of the same magnitude in both treatment
groups.
The total percentage of cytoplasmic staining and the
total percentage of membrane staining were highly corre-
lated (r = 0.92). EGFR expression, as measured by mem-
brane staining, had the strongest prognostic eVect of the
two, and conditioned on this eVect, cytoplasmic staining
had no prognostic eVect of its own. All further analyses
were consequently focused on membrane staining. The per-
centage of membrane staining had a statistically signiWcant
prognostic eVect as a continuous covariate in both treat-
ment groups (placebo, P = 0.0147; geWtinib, P = 0.0463)
and in both groups combined (P = 0.0025) (Table 1). In the
placebo group, the most statistically signiWcant variable
was membrane staining of weak (1+), moderate (2+) or
strong (3+) intensity, whereas in the geWtinib group it was
the variable “membrane staining of moderate (2+) or strong
(3+) intensity”. According to the prespeciWed procedure,
two variables, “membrane staining of weak (1+)” and
“moderate (2+) or strong (3+)”, were analyzed based on
both treatment groups combined, resulting in identifying
membrane staining of weak (1+), moderate (2+), or strong
(3+) intensity as the most statistically signiWcant variable.
As membrane staining is a continuous covariate, the eVect
of membrane staining is a trend eVect. The hazard ratio
(HR) is calculated based on membrane staining of 0 or
100%, only.
The prognostic eVect of both EGFR-related variables
(growth pattern and membrane staining) is of the same size123
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pendent of other prognostic factors (Table 1). A further
exploration of the trend eVect is shown in Fig. 2a (solid
growth pattern) and b (glandular growth pattern), which
show the median survival times predicted by the Cox pro-
portional hazard model, incorporating membrane staining
as a continuous covariate, i.e., a trend eVect of membrane
staining. As shown in Fig. 2a and b, with many groups con-
taining small numbers of patients, it was expected that the
variability of the estimated medians around the predicted
trend was large, indicated by the wide conWdence intervals
(CIs). In all cases, where both upper and lower 99% conW-
dence limits could be estimated, the interval included the
median time predicted by the Cox proportional hazard trend
model, suggesting a reasonable model Wt. However, a lack
of Wt test rejected the null hypothesis that the data Wtted the
Cox proportional hazard trend model (P = 0.0240). The
lack of Wt may be caused by deviation from the trend
model, or because of a lack of proportional hazard.
The prognostic trend eVect appears to be more pro-
nounced in patients having a glandular growth pattern
(Fig. 2b) than in those having a solid growth pattern
(Fig. 2a). Since the interaction eVect between growth pat-
tern and percentage membrane staining was not statistically
signiWcant (P = 0.1474), the prognostic trend eVect may be
the same for all patients. In spite of this, the prognostic
trend eVect in the glandular growth pattern group was
highly statistically signiWcant (P = 0.0035), whereas the
trend eVect in the solid growth pattern group was not statis-
tically signiWcant (P = 0.1094), yet another possibility is
that percentage membrane staining only has a prognostic
trend eVect in the group of patients not having a solid
growth pattern.
Prognostic eVect using alternative scoring method
An additional post-hoc analysis of the EGFR expression
data from the INTACT trials was conducted, to facilitate a
Table 1 Prognostic eVects of EGFR variables
a Number of subjects (N)/number of events (E). Event is death
b Missing values for prognostic factors in three cases
* Simultaneous test of both growth pattern and membrane staining
P-values are for the null hypothesis (1) of no eVect of growth pattern group and (2) of no eVect of membrane staining of weak (1+) or moderate
(2+) or strong (3+) intensity. Because membrane staining of weak intensity (1+) did not show statistical signiWcance in the geWtinib group the P-
value in this group is for the null hypothesis (3) no eVect of membrane staining of moderate (2+) or strong (3+) intensity
Analysis based on Solid N/Ea Glandular N/Ea Factor P value HR (95% CIs)
Placebo group 108/80 56/34 Glandular/solid (1) 0.0220 0.604 (0.392–0.93)
Placebo group 100%/0% Membrane staining (2) 0.0147 0.521 (0.309–0.880)
Placebo group Both (*) 0.0128
GeWtinib group 223/161 129/74 Glandular/solid (1) 0.0014 0.628 (0.472–0.835)
GeWtinib group 100%/0% Membrane staining (3) 0.0463 0.687 (0.475–0.994)
GeWtinib group Both (*) 0.0023
Placebo and geWtinib groups 331/241 185/108 Glandular/solid (1) 0.0001 0.631 (0.499–0.798)
Placebo and geWtinib groups 100%/0% Membrane staining (2) 0.0025 0.642 (0.482–0.856)
Placebo and geWtinib groups Both (*) <0.0001
Both groups conditioned on eVect of 
other prognostic factors
329/240 184/108b (1) 0.0011 0.668 (0.525–0.850)
(2) 0.0158 0.694 (0.516–0.934)
Fig. 2 a Estimated median survival times for patients with tumors
having a solid growth pattern (including 99% CIs). *Estimation not
possible. b Estimated median survival times for patients with tumors
having a glandular growth pattern (including 99% CIs). *Estimation
not possible; **estimation not possible: 406 days inserted in Wgures;
***estimation not possible: 573 days inserted in Wgures123
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of the erlotinib BR21 trial (Shepherd et al. 2005). In this
analysis, EGFR-positive was deWned as ¸10% of cells
staining positive for EGFR. Using this scoring system, 459
(89%) and 57 (11%) patients were found to be EGFR-posi-
tive and EGFR-negative, respectively. When both treat-
ments groups were combined, the median survival for the
EGFR-positive group was 307 days with 261 days for the
EGFR-negative group; the HR comparing the positive to
negative groups was 0.812 (95% CI = 0.588–1.123), sug-
gesting similar results to the original analysis that patients
with EGFR expression have a better prognosis in this study.
To look for a predictive eVect, the geWtinib treatment group
contained 312 EGFR-positive and 40 EGFR-negative
classed patients with a median survival 296 and 218 days,
respectively. An HR of 0.959 (95% CI = 0.635–1.449) was
estimated in Cox regression analysis with a P value of 0.84.
Comparison with other clinical prognostic factors
To illustrate how strong the prognostic eVect of the two
EGFR-related variables is (growth pattern and staining
intensity), the eVect of these variables was compared with
other well-known clinical prognostic factors.
The strength of the eVect of the EGFR prognostic factor
related to growth pattern expressed as an HR (solid vs.
glandular) was 0.668 (95% CI = 0.525–0.850) (Table 1).
This was comparable to the strength of the eVect of other
well-known clinical prognostic factors such as disease
stage (HR for stage IV vs. stage III: 0.695 [95% CI =
0.523–0.923]), liver metastasis (HR for present vs. not
present: 0.718 [95% CI = 0.546–0.946]), and bone metasta-
sis (HR for present vs. not present: 0.730 [95% CI = 0.566–
0.941]). Only the eVect of PS appeared to be stronger (HR
for ‘2’ vs. ‘0 or 1’: 0.484 [95% CI = 0.351–0.667]). The
strength of the prognostic eVect of membrane staining at
weak (1+), moderate (2+), or strong (3+) intensity, when
shifting from 0 to 100%, was similar. This maximum shift
from 0 to 100% membrane staining gave a 30% improve-
ment in survival (HR 0.694; 95% CI = 0.516–0.934)
(Table 1).
To further illustrate the strength of the prognostic eVect
of the two EGFR-related variables, the Kaplan–Meier plots
for growth pattern (Fig. 3a) and membrane staining
(Fig. 3b) were compared with those for disease stage III
versus IV (Fig. 3c), as stage of disease showed the stron-
gest prognostic eVect in the original INTACT eYcacy
analysis.
Relationship between growth pattern and histology
Because it was expected that histology and growth pattern
were at least partially confounded, it was further investi-
gated whether growth pattern had an independent eVect
which could not be explained by the recorded histology on
the original six-category scale. This was done in spite of the
fact that the dichotomized histology variable (AC [includ-
ing BAC] vs. other histologies) did not have a statistically
signiWcant prognostic eVect on survival.
Since all BACs had a glandular growth pattern, it was
not possible to distinguish an eVect of histology and growth
pattern. BAC, which is a subgroup of AC, was therefore
excluded when investigating dependence between histol-
ogy and growth pattern (14 patients with eight deaths).
The analysis showed that the eVect of the two EGFR
prognostic factors (growth pattern and membrane staining)
Fig. 3 a Prognostic eVect of 
growth pattern illustrated by 
Kaplan–Meier plot for survival. 
b Prognostic eVect of membrane 
staining illustrated by Kaplan–
Meier plot for survival. c Prog-
nostic eVect of disease stage 
illustrated by Kaplan–Meier plot 
for survival123
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excluding BAC (P = 0.0019 and P = 0.0137, respectively).
The strength of the eVect of the two EGFR prognostic fac-
tors was similar to that observed when all (516) specimens
were analyzed (data not shown). It is not relevant to test the
eVect of growth pattern in the group of non ACs. The eVect
of membrane staining was more pronounced in the AC
group than in the heterogeneous group of patients with
other histologies (excluding BAC), HRs being 0.60 (95%
CI = 0.40–0.90) and 0.75 (95% CI = 0.47–1.17), respec-
tively.
Relationship between growth pattern and histology 
to mutation and ampliWcation of EGFR
A post-hoc analysis was conducted to look at the eVect of
EGFR mutation and ampliWcation status on the results seen
for staining intensity and growth pattern in a subset of
patients also looked at in the recent report by Bell et al.
(2005) (Bell et al. 2005). Of the 516 patients in the analysis
of staining intensity and growth pattern, 246 (47.7%) had
suYcient DNA for EGFR mutation testing and 387 (75%)
had suYcient DNA for measurement of gene ampliWcation
by DNA sequencing. For EGFR mutation, 25 (20.2%)
patients were found to contain an EGFR mutation while
225 were classiWed as mutation-negative, leaving 270 with
missing EGFR-mutation status. For EGFR ampliWcation,
25 (6.4%) patients had EGFR gene ampliWcation, 362
(93.6%) were EGFR ampliWcation-negative, with 129 clas-
siWed as “missing”.
For the statistical analysis, three groups were considered,
“positive” (either deWned as containing mutation or ampliW-
cation in the respective analysis), “negative” or “missing”.
AmpliWcation was found to have no eVect or correlation
with either staining intensity or growth pattern, and also
had no prognostic eVect alone in a model with both treat-
ments combined. For the analysis of EGFR mutation in the
model with staining intensity and growth pattern, EGFR
mutation was found to be prognostic (P = 0.03), and both
staining intensity (P = 0.007) and growth pattern
(P = 0.0005) maintained signiWcant prognostic eVects as
well.
Predictive eVect
Neither the growth pattern nor the EGFR membrane stain-
ing variable had a statistically signiWcant predictive eVect.
This was illustrated in an analysis of a model including
treatment, growth pattern (solid vs. glandular group) and
membrane staining, together with the interactions between
treatment and growth pattern, and treatment and membrane
staining. The P values for the test of interactions in this
model were P = 0.8688 for treatment and growth pattern,
and P = 0.4967 for treatment and membrane staining.
Based on this model, including the eVects of the two inter-
actions, the HR and corresponding 95% CI between geWti-
nib and placebo were estimated for four populations: each
of the growth patterns, solid and glandular, with either 0 or
100% membrane staining (Table 2). The wide CIs within
each of the four populations indicate that even though no
statistically signiWcant predictive eVect was found, the sam-
ple sizes were not large enough to exclude the existence of
a clinically signiWcant predictive eVect.
Discussion
The results from the current analysis of the two large, Phase
III INTACT 1 and 2 studies represent the largest analysis of
EGFR expression and OS in patients with NSCLC to date.
The INTACT results provide highly statistically signiWcant
evidence that EGFR expression, as measured by percent-
age-membrane staining using the EGFR pharmDx™ assay,
is a strong independent prognostic indicator for improved
survival in patients treated with platinum-based chemother-
apy with tumors that exhibit glandular growth pattern. It
may be speculated whether the prognostic trend eVect
found in the present studies reXects a true prognostic eVect
of EGFR staining in tumors with glandular growth pattern,
or whether these tumors respond better to Wrst-line plati-
num-based chemotherapy.
The prognostic trend eVect of percentage-membrane
staining in patients with a solid growth pattern is more
uncertain, ranging from no eVect to the same eVect as for
patients with a glandular growth pattern (Bingle et al. 2005).
Table 2 Estimates of the eVect of treatment (predictive eVect) in four diVerent groups deWned by EGFR variables
a Number of subjects (N)/number of events (E). Event is death
b HR, hazard ratio for treatment eVect (geWtinib/placebo)
DeWnition of group N/Ea GeWtinib N/Ea Placebo HRb (95% CIs)
Solid growth pattern and membrane staining = 0% 23/15 12/11 0.876 (0.522–1.471)
Glandular growth pattern and membrane staining = 0% 17/11 5/5 0.840 (0.496–1.423)
Solid growth pattern and membrane staining = 100% 86/60 43/30 1.087 (0.786–1.504)
Glandular growth pattern and membrane staining = 100% 38/15 11/6 1.042 (0.632–1.719)123
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well-diVerentiated AC (i.e., glandular growth pattern com-
prised of AC, BAC, and adenosquamous carcinomas) had
better survival than those with tumors that had a solid
growth pattern.
In addition to prognostic factors, which have eVects on
survival irrespective of treatment, much research is being
undertaken in an attempt to identify factors that may predict
response to treatment. The results from the present analysis
showed that neither growth pattern nor EGFR-membrane
staining had a statistically signiWcant predictive eVect.
However, the study may have been limited by power, given
that tumor samples were not mandatory and were only
obtained from less than one-third of patients. Furthermore,
in these INTACT studies, geWtinib was in combination with
chemotherapy and any geWtinib-treatment eVect may have
been masked by the combination. Additionally, given the
overall result of both trials, in which addition of geWtinib to
chemotherapy did not result in superior eYcacy, a predic-
tive eVect is less likely to be seen.
Results from the TALENT (Tarceva Responses in Con-
junction with Cisplatin and Gemcitabine) and TRIBUTE
(Tarceva Responses in Conjunction with Paclitaxel and
Carboplatin) studies demonstrated that the addition of
another EGFR-TKI, in this case erlotinib, to standard che-
motherapy regimens also did not improve outcome for che-
motherapy-naive patients with advanced NSCLC (Herbst
et al. 2005). As with INTACT 1 and 2, and geWtinib, the
level of EGFR expression in both TALENT and TRIBUTE
were not predictive of responses to erlotinib (Gatzemeier
et al. 2007; Herbst et al. 2004, 2005).
Exploratory analysis of 157 tumor biopsies from patients
participating in the Phase II IDEAL (IRESSA Dose Evalua-
tion in Advanced Lung cancer) trials revealed that tumor
EGFR-membrane staining is not clinically relevant for pre-
dicting response in patients receiving geWtinib mono-
therapy for pretreated advanced NSCLC (Bailey et al.
2003).
In the Phase III ISEL (IRESSA Survival Evaluation in
Lung cancer) trial that failed to demonstrate an overall sur-
vival of geWtinib as compared to placebo in patients who
had failed chemotherapy (Thatcher et al. 2005), analysis of
tumor biopsy samples demonstrated that EGFR protein
expression-positive patients achieved signiWcantly better
survival with geWtinib versus placebo than patients with
EGFR protein expression-negative tumors (interaction test
for EGFR protein expression-positive vs. EGFR protein
expression-negative patients, P = 0.049). Better response
rates were also reported for EGFR protein expression-posi-
tive patients than EGFR protein expression-negative
patients (8.2 vs. 1.5%) (Hirsch et al. 2006). Furthermore,
results from the randomized, placebo-controlled trial of erl-
otinib in patients with locally advanced or metastatic
NSCLC after failure of at least one chemotherapy regimen
(BR21), suggest a correlation between EGFR expression
and survival (Shepherd et al. 2005; Tsao et al. 2005). Erl-
otinib prolonged survival in the EGFR-positive subgroup
(n = 184; HR 0.68; 95% CI = 0.49–0.95; P = 0.02), but did
not appear to have an eVect on survival in the EGFR-nega-
tive subgroup (n = 141; HR 0.93; 95% CI = 0.63–1.36;
P = 0.70).
As EGFR expression was measured using a diVerent
scoring method in the erlotinib BR21 trial from that used in
this analysis of EGFR in the INTACT trials, an additional
post-hoc analysis (data not shown) was conducted looking
at the eVect of EGFR expression with the same deWnition,
from BR21 (¸10% of cells staining positive equals EGFR-
positive). This analysis suggested no statistically signiWcant
diVerences between EGFR-positive and -negative patients,
when treated with geWtinib in combination with chemother-
apy.
Emerging data indicate that mutations in the EGFR gene
are associated with dramatic responses to geWtinib (Lynch
et al. 2004; Paez et al. 2004; Sordella et al. 2004). Mutation
analysis of samples from INTACT 1 and 2 did not show a
statistically signiWcant diVerence in response to geWtinib
plus chemotherapy according to EGFR genotype (Bell et al.
2005). OS was not aVected by the addition of geWtinib to
chemotherapy in patients with EGFR mutations
(HR = 1.77; 95% = CI 0.50–6.23). However, patients with
EGFR-mutation-positive tumors treated with chemotherapy
alone had a better OS compared to patients with mutation-
negative tumors (median OS, 19.4 vs. 9.2 months;
HR = 0.48; 95% CI = 0.29–0.82), raising the possibility
that this genetically deWned subset of NSCLC may have a
more favorable natural history, and that EGFR mutations
may also serve as a prognostic factor. Our analysis of a sub-
set of these same patients included in the current analysis
Wnds similar results for the prognostic eVect.
As in other reports, mutational status of tumors from
BR21 was shown to possibly increase responsiveness to
erlotinib. The response rate among patients with mutations
was twice that among patients with wild-type EGFR,
although the diVerence was not signiWcant, perhaps because
the number of responses was small: 7% of those with wild-
type EGFR had a response compared with 16% of those
with an EGFR mutation (P = 0.37) (Tsao et al. 2005).
Importantly however, the risk of death did not diVer signiW-
cantly among patients with EGFR mutations who received
erlotinib compared with patients who received placebo
(HR = 0.77; 95% CI = 0.40–1.50; P = 0.54), or among
patients with wild-type EGFR who received erlotinib com-
pared with such patients who received placebo (HR = 0.73;
95% CI = 0.49–1.10; P = 0.13).
In a recent report from Eberhard et al. (Eberhard et al.
2005; Kishi et al. 2005), EGFR mutations were found in123
J Cancer Res Clin Oncol (2009) 135:467–476 47513% of tumor samples from patients treated in the TRIB-
UTE study (Herbst et al. 2005) and was associated with
longer survival irrespective of treatment (P < 0.001). This
data suggests that EGFR mutation is prognostic of longer
survival rather than predictive. However, among patients
treated with erlotinib, EGFR mutations were associated
with a better response rate and trend towards better time to
progression but no survival increase (P < 0.05, 0.092 and
0.96, respectively). On the other hand, K-ras mutations
were associated with a signiWcant decrease in time to pro-
gression and survival in patients treated with erlotinib.
Many other biomarkers are under investigation as pre-
dictive factors, for example, the components of the Akt and
MAPK signaling pathways. Indeed, patients with tumors
that were positive for phosphorylated Akt (pAkt) have been
shown to have a better response rate, disease control rate,
and time to progression with geWtinib than those that were
negative (Cappuzzo et al. 2004). The data from 78 patients
treated in Japan with geWtinib showed that pAkt was not
predictive of response (Kishi et al. 2005).
Further work has investigated the relationship between
EGFR gene copy number (assessed by Xuorescence in situ
hybridization [FISH]), EGFR mutations, EGFR protein
expression and Akt activation status as predictive markers
for geWtinib therapy in advanced NSCLC (Cappuzzo et al.
2005). In a multivariable analysis, high EGFR gene copy
number was signiWcantly associated with better survival
(HR = 0.44; 95% CI = 0.23–0.82), indicating that this may
be a molecular predictor for geWtinib eYcacy in advanced
NSCLC. The analysis of tumor biopsy samples from
patients participating in the ISEL trial has also demon-
strated that high EGFR gene copy number was a predictor
of increased survival with geWtinib (comparison of HRs
high vs. low copy number, P = 0.045) (Hirsch et al. 2006).
AmpliWcation of EGFR was associated with responsiveness
to erlotinib (P = 0.03) in tumor samples from BR21 sub-
jected to FISH (Tsao et al. 2005).
The current analysis in Wrst-line, platinum-based, che-
motherapy-treated patients with NSCLC provides statisti-
cally signiWcant evidence that the combination of EGFR
expression and growth pattern is a strong prognostic indica-
tor for improved survival within this setting.
The prognostic trend eVect of percentage membrane
staining in patients with a solid growth pattern is more
uncertain, ranging from no eVect to the same eVect as for
patients with a glandular growth pattern. In this analysis,
patients with tumors exhibiting areas with well-diVerenti-
ated AC (i.e., glandular growth pattern) had better survival
than those with tumors that had a solid growth pattern. This
is in agreement with earlier studies, which have shown that
NSCLC patients with well-diVerentiated tumors survive
longer than patients with poorly diVerentiated tumors
(Gawrychowski et al. 2003; Nakayama et al. 1997).
In summary, many factors may have contributed to the
lack of a survival beneWt for geWtinib in combination with
Wrst-line platinum-based chemotherapy. The debate contin-
ues on the usefulness of EGFR expression to help select
patients for treatment. The combination of EGFR expres-
sion and growth pattern may be a strong prognostic indica-
tor for improved survival, while high EGFR gene copy
number and EGFR mutations could be associated with bet-
ter response to EGFR-TKIs.
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